Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KD2-396
- Development stage
- Unknown
- Lead developer
- The Chemo-Sero-Therapeutic Research Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**KD2-396** is an investigational pediatric hexavalent prophylactic combination vaccine being developed in Japan by KM Biologics and Meiji Seika Pharma. It combines vaccine components intended to prevent pertussis, diphtheria, tetanus, poliomyelitis, *Haemophilus influenzae* type b infection, and hepatitis B; the program adds a hepatitis B antigen component to an established five-component pediatric vaccine platform. A randomized Phase III study in infants began enrollment on March 25, 2026. ([meiji-seika-pharma.co.jp](https://www.meiji-seika-pharma.co.jp/pressrelease/2026/detail/pdf/260326_01.pdf))
- Other names
- KD2396KD-2396KD 2396
Beyond the preview
Go deeper on KD2-396.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KD2-396.